VC  Schroder Ventures Life Sciences

http://www.svlsa.com





     Office Locations:

One Boston Place
201 Washington Street Suite 3900
Boston, MA 020108
Phone: 617-367-8100
Fax: 617-367-1590

 

Stages:

  • Early
  • Expansion
  • Growth
  • Seed


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five private venture capital funds with approximately $2.0 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco. SVLS was started in London as Schroder Ventures Life Sciences in 1993 as part of the Schroder Ventures Group. SVLS became independent of the Schroder Ventures Group in 2001, and in January 2005 changed its name to SV Life Sciences to reflect independent ownership. The firm usually commits $1 to $40 million per company, diversifying its portfolio by sub sector, geography and stage of company. SVLSFV closed in June 2010 with total commitments of $513m (plus $11 million of co-investments committed by partners and individuals affiliated with SVLS). As of September 2011 the Fund had invested $78m in 19 portfolio companies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    David Milne Managing Partner
    Denise Marks Partner and CFO
    Eugene Hill Managing Partner, Chairman
    james Garvey Chairman Emeritus
    Joshua Resnick Partner

     

    Portfolio companies include:


      Accelecare Wound Centers
        web link


      Acufocus
        web link


      Adimab
        web link


      Alba Therapeutics
        web link


      Alinea Pharmaceuticals


      AllianceCare


      AlloCure
        web link


      Amgen
        web link


      AqueSys
        web link


      Archemix
        web link


      Arsanis
        web link


      Autifony Therapeutics
        web link


      Bicycle Therapeutics
        web link


      Broadlane
        web link


      Cadent Technologies
        web link


      CardioKinetix
        web link


      Catabasis Pharmaceuticals
        web link


      Convergence Pharmaceuticals
        web link


      Coridea
        web link


      Cyterix Pharmaceuticals
        web link


      Lombard Medical
        web link


      NeoVista
        web link


      Quick Study Radiology
        web link


     

    Recent News:


      There is no recent news for Schroder Ventures Life Sciences.